1 分钟阅读
May 9 (Reuters) - Cellectar Biosciences Inc:
* CELLECTAR GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT RHABDOMYOSARCOMA Source text for Eikon: Further company coverage: